HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.048520v1 49/2/201    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Dehdashti, F. Articles by Welch, M. J. PubMed PubMed Citation Articles by Dehdashti, F. Articles by Welch, M. J.

Assessing Tumor Hypoxia in Cervical Cancer by PET with ⁶⁰Cu-Labeled Diacetyl-Bis(N⁴-Methylthiosemicarbazone)

¹ Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri; ² Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; ³ Division of Radiological Sciences, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri; and ⁴ Department of Radiation Oncology, Edward Mallinckrodt Institute of Radiology, St. Louis, Missouri

Correspondence: For correspondence or reprints contact: Farrokh Dehdashti, MD, Edward Mallinckrodt Institute of Radiology, 510 South Kingshighway Blvd., St. Louis, MO 63110. E-mail: dehdashtif{at}mir.wustl.edu

Tumor hypoxia indicates a poor prognosis. This study was undertaken to confirm our prior pilot results showing that pretreatment tumor hypoxia demonstrated by PET with ⁶⁰Cu-labeled diacetyl-bis(N⁴-methylthiosemicarbazone) (⁶⁰Cu-ATSM) is a biomarker of poor prognosis in patients with cervical cancer. Thirty-eight women with biopsy-proved cervical cancer underwent ⁶⁰Cu-ATSM PET before the initiation of radiotherapy and chemotherapy. ⁶⁰Cu-ATSM uptake was evaluated semiquantitatively as the tumor-to-muscle activity ratio (T/M). A log-rank test was used to determine the cutoff uptake value that was strongly predictive of prognosis. All patients also underwent clinical PET with ¹⁸F-FDG before the institution of therapy. The PET results were correlated with clinical follow-up. Tumor ⁶⁰Cu-ATSM uptake was inversely related to progression-free survival and cause-specific survival (P = 0.006 and P = 0.04, respectively, as determined by the log-rank test). We found that a T/M threshold of 3.5 best discriminated patients likely to develop a recurrence from those unlikely to develop a recurrence; the 3-y progression-free survival of patients with normoxic tumors (as defined by T/M of 3.5) was 71%, and that of patients with hypoxic tumors (T/M of >3.5) was 28% (P = 0.01). Tumor ¹⁸F-FDG uptake did not correlate with ⁶⁰Cu-ATSM uptake, and there was no significant difference in tumor ¹⁸F-FDG uptake between patients with hypoxic tumors and those with normoxic tumors (P = 0.9). Pretherapy ⁶⁰Cu-ATSM PET provides clinically relevant information about tumor oxygenation that is predictive of outcome in patients with cervical cancer.

Key Words: PET • ⁶⁰Cu-ATSM • hypoxia • cervical cancer • survival

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				J. S. Lewis, R. Laforest, F. Dehdashti, P. W. Grigsby, M. J. Welch, and B. A. Siegel An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix J. Nucl. Med., July 1, 2008; 49(7): 1177 - 1182. [Abstract] [Full Text] [PDF]